GlassScriptPhysician profile
Stanley Barnes
NPI 1518915255
$2,571.31
in general payments reported to CMS, 2019-2025
36 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $110 · 2021: $192 · 2022: $683 · 2023: $351 · 2024: $306 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $357.10 | 2019-2025 | Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $330.08 | 2022-2025 | |
| Novo Nordisk INC | $275.87 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $208.85 | 2021-2025 | Trelegy Ellipta |
| Abbvie INC. | $158.52 | 2022-2025 | Vraylar |
| Pfizer INC. | $133.23 | 2019-2025 | |
| Lilly USA, LLC | $126.21 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $105.74 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $99.68 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.81 | 2022-2024 | Relistor, Xifaxan, Trulance |
| Amarin Pharma, INC. | $70.32 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $69.68 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $58.30 | 2019-2025 | Zoryve |
| Xeris Pharmaceuticals, INC. | $49.20 | 2023 | Gvoke Hypopen |
| Corcept Therapeutics | $35.13 | 2023-2024 | Korlym |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $34.12 | 2023-2025 | Ibsrela |
| Exact Sciences Corporation | $33.17 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $33.05 | 2022-2024 | Eliquis |
| Mylan Specialty L.P. | $32.29 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.55 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.32 | 2020-2025 | Jardiance |
| Abbott Laboratories | $21.49 | 2022 | |
| Axsome Therapeutics, INC. | $18.13 | 2024 | Auvelity |
| Almatica Pharma LLC | $17.55 | 2023 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $16.99 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.09 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $15.05 | 2023 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $15.03 | 2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $14.83 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.53 | 2019 | |
| Amgen INC. | $14.12 | 2019 | |
| Genentech USA, INC. | $11.83 | 2019 | |
| Allergan, INC. | $11.65 | 2019 | |
| Shire North American Group INC | $11.19 | 2019 | |
| Eisai INC. | $11.09 | 2021 | |
| Sumitomo Pharma America, INC. | $7.52 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.